Table II.
The immunoreactive scores of phosphorylated various kinases in abnormal blood vessels from 11 patients with port-wine stain
| Patient | Age | Sample | pJNK* (G7, 6254) | pERK* (E4, 7383) | pP70S6K* (A6, 8416) | pAKT* (7985-R) | pPI3K† (4228) | pmTOR† (49F9, 2976) | pPLC-γ† (2821) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Infant | Scalp | 2 | 4 | 4 | 0 | 0 | 0 | 0 |
| Normal | 1 | 0 | 4 | 0 | 0 | 0 | 0 | ||
| 2 | Infant | Extremity | 2 | 0 | 6 | 0 | 0 | 0 | 0 |
| Normal | 0 | 0 | 6 | 0 | 0 | 0 | 0 | ||
| 3 | Adult | Extremity | 2 | 1 | 4 | 0 | 0 | 0 | 0 |
| Normal | 0 | 0 | 4 | 0 | 0 | 0 | 0 | ||
| 4 | Adult | Scalp | 6 | 2 | 6 | 1 | 0 | 0 | 0 |
| Normal | 1 | 0 | 6 | 0 | 0 | 0 | 0 | ||
| 5 | Adult | Scalp | 4 | 4 | 4 | 0 | 0 | 0 | 0 |
| Normal | 1 | 0 | 4 | 0 | 0 | 0 | 0 | ||
| 6 | Adult | Facial | 4 | 6 | 6 | 4 | 2 | 0 | 0 |
| Normal | 0 | 0 | 6 | 0 | 0 | 0 | 0 | ||
| Neck | 4 | 6 | 6 | 4 | 1 | 0 | 0 | ||
| 7 | Adult | Facial | 4 | 6 | 6 | 6 | 2 | 0 | 0 |
| Extremity | 4 | 6 | 6 | 4 | 2 | 0 | 0 | ||
| 8 | Adult | Facial | 4 | 4 | 6 | 0 | 0 | 0 | 0 |
| Edge | 4 | 2 | 6 | 2 | 0 | 0 | 0 | ||
| 9 | Adult | Facial | 6 | 6 | 6 | 1 | 0 | 0 | 0 |
| Edge | 6 | 6 | 6 | 0 | 0 | 0 | 0 | ||
| 10 | Adult | Facial | 6 | 6 | 6 | 1 | 0 | 0 | 0 |
| Edge | 6 | 4 | 6 | 0 | 1 | 0 | 0 | ||
| 11 | Adult | Facial | 6 | 6 | 6 | 2 | 0 | 0 | 0 |
| Edge | 6 | 4 | 6 | 2 | 2 | 0 | 0 | ||
| Nodular-1 | 6 | 6 | 6 | 4 | 4 | 0 | 6 | ||
| Nodular-2 | 4 | 4 | 2 | 2 | 2 | 0 | 2 |
Edge, Edge of port-wine stain lesion sites; nodular, nodular port-wine stain; normal, the adjacent normal-appearing skin (0.5–1 cm away from port-wine stain lesion sites).
*
Antibodies from Santa Cruz Biotechnology, Inc, Santa Cruz, CA.
†
Antibodies from Cell Signaling, Inc, Danvers, MA.